Literature DB >> 15910551

Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application.

Claus Pietrzik1, Christian Behl.   

Abstract

To date, various strategies have been developed in order to prevent or to slow down the progression of Alzheimer's disease (AD). Despite the medical need for an effective therapeutic treatment of AD, progress towards this goal is painstakingly slow. Although AD is the most common neurodegenerative disorder and a large amount of primary basic and clinical research has been performed already, it appears very difficult to identify appropriate targets, which would promise fast, effective and safe strategies to combat the disease onset and progression. In this review, we present some of clinically applied treatment options, which may improve AD symptoms for a short period but so far lack the ability to prevent or halt this devastating disease. Additionally, we summarize some of the experimental approaches in AD therapy, which might lead to the development of more promising drugs in the future.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15910551      PMCID: PMC2517414          DOI: 10.1111/j.0959-9673.2005.00435.x

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  72 in total

Review 1.  Abeta as a bioflocculant: implications for the amyloid hypothesis of Alzheimer's disease.

Authors:  Stephen R Robinson; Glenda M Bishop
Journal:  Neurobiol Aging       Date:  2002 Nov-Dec       Impact factor: 4.673

Review 2.  Antioxidants as treatment for neurodegenerative disorders.

Authors:  Bernd Moosmann; Christian Behl
Journal:  Expert Opin Investig Drugs       Date:  2002-10       Impact factor: 6.206

3.  Treatment of Alzheimer's disease: current status and new perspectives.

Authors:  Elio Scarpini; Philip Scheltens; Howard Feldman
Journal:  Lancet Neurol       Date:  2003-09       Impact factor: 44.182

Review 4.  [Pathomechanisms and hypothesis-guided therapeutic strategies for late-onset Alzheimer's disease].

Authors:  S Hoyer; P Riederer
Journal:  Fortschr Neurol Psychiatr       Date:  2003-07       Impact factor: 0.752

5.  The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing.

Authors:  Claus U Pietrzik; Tracy Busse; David E Merriam; Sascha Weggen; Edward H Koo
Journal:  EMBO J       Date:  2002-11-01       Impact factor: 11.598

6.  Memantine in moderate-to-severe Alzheimer's disease.

Authors:  Barry Reisberg; Rachelle Doody; Albrecht Stöffler; Frederick Schmitt; Steven Ferris; Hans Jörg Möbius
Journal:  N Engl J Med       Date:  2003-04-03       Impact factor: 91.245

7.  Reconstitution of gamma-secretase activity.

Authors:  Dieter Edbauer; Edith Winkler; Joerg T Regula; Brigitte Pesold; Harald Steiner; Christian Haass
Journal:  Nat Cell Biol       Date:  2003-05       Impact factor: 28.824

8.  Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

Authors:  James A R Nicoll; David Wilkinson; Clive Holmes; Phil Steart; Hannah Markham; Roy O Weller
Journal:  Nat Med       Date:  2003-03-17       Impact factor: 53.440

Review 9.  Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.

Authors:  Krista L Lanctôt; Nathan Herrmann; Kenneth K Yau; Lyla R Khan; Barbara A Liu; Maysoon M LouLou; Thomas R Einarson
Journal:  CMAJ       Date:  2003-09-16       Impact factor: 8.262

10.  Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

Authors:  Christoph Hock; Uwe Konietzko; Johannes R Streffer; Jay Tracy; Andri Signorell; Britta Müller-Tillmanns; Ulrike Lemke; Katharina Henke; Eva Moritz; Esmeralda Garcia; M Axel Wollmer; Daniel Umbricht; Dominique J F de Quervain; Marc Hofmann; Alessia Maddalena; Andreas Papassotiropoulos; Roger M Nitsch
Journal:  Neuron       Date:  2003-05-22       Impact factor: 17.173

View more
  11 in total

1.  Enhanced brain amyloid-β clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease.

Authors:  Hisham Qosa; Alaa H Abuznait; Ronald A Hill; Amal Kaddoumi
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

2.  Polysaccharides from wolfberry antagonizes glutamate excitotoxicity in rat cortical neurons.

Authors:  Yuen-Shan Ho; Man-Shan Yu; Suet-Yi Yik; Kwok-Fai So; Wai-Hung Yuen; Raymond Chuen-Chung Chang
Journal:  Cell Mol Neurobiol       Date:  2009-12       Impact factor: 5.046

3.  Response surface methodology in docking study of small molecule BACE-1 inhibitors.

Authors:  Nima Razzaghi-Asl; Ahmad Ebadi; Najmeh Edraki; Ahmadreza Mehdipour; Sara Shahabipour; Ramin Miri
Journal:  J Mol Model       Date:  2012-05-13       Impact factor: 1.810

Review 4.  Endothelial LRP1 - A Potential Target for the Treatment of Alzheimer's Disease : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla.

Authors:  Steffen E Storck; Claus U Pietrzik
Journal:  Pharm Res       Date:  2017-09-25       Impact factor: 4.200

5.  The selective beta1-adrenoceptor antagonist nebivolol is a potential oestrogen receptor agonist with neuroprotective abilities.

Authors:  D Manthey; M Gamerdinger; C Behl
Journal:  Br J Pharmacol       Date:  2010-02-01       Impact factor: 8.739

Review 6.  Antioxidant therapy in Alzheimer's disease: theory and practice.

Authors:  Gjumrakch Aliev; Mark E Obrenovich; V Prakash Reddy; Justin C Shenk; Paula I Moreira; Akihiko Nunomura; Xiongwei Zhu; Mark A Smith; George Perry
Journal:  Mini Rev Med Chem       Date:  2008-11       Impact factor: 3.862

7.  Design, synthesis, and evaluation of novel cinnamic acid-tryptamine hybrid for inhibition of acetylcholinesterase and butyrylcholinesterase.

Authors:  Shahrzad Ghafary; Roshanak Ghobadian; Mohammad Mahdavi; Hamid Nadri; Alireza Moradi; Tahmineh Akbarzadeh; Zahra Najafi; Mohammad Sharifzadeh; Najmeh Edraki; Farshad Homayouni Moghadam; Mohsen Amini
Journal:  Daru       Date:  2020-05-05       Impact factor: 3.117

8.  Water extract from the leaves of Withania somnifera protect RA differentiated C6 and IMR-32 cells against glutamate-induced excitotoxicity.

Authors:  Hardeep Kataria; Renu Wadhwa; Sunil C Kaul; Gurcharan Kaur
Journal:  PLoS One       Date:  2012-05-14       Impact factor: 3.240

9.  Fragment-based Binding Efficiency Indices in Bioactive Molecular Design: A Computational Approach to BACE-1 Inhibitors.

Authors:  Nima Razzaghi-Asl; Ahmad Ebadi; Najmeh Edraki; Sara Shahabipour; Ramin Miri
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

10.  Altered APP Carboxyl-Terminal Processing Under Ferrous Iron Treatment in PC12 Cells.

Authors:  Chi Hyun Kim; Yeong-Min Yoo
Journal:  Korean J Physiol Pharmacol       Date:  2013-06-11       Impact factor: 2.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.